Sensitivity of novel SARS-CoV-2 Omicron subvariants, BA.2.11, BA.2.12.1, BA.4 and BA.5 to therapeutic monoclonal antibodies
Sensitivity of novel SARS-CoV-2 Omicron subvariants, BA.2.11, BA.2.12.1, BA.4 and BA.5 to therapeutic monoclonal antibodies
Abstract As of May 2022, Omicron BA.2 variant is the most dominant variant in the world. Thereafter, Omicron subvariants have emerged and some of them began outcompeting BA.2 in multiple countries. For instance, Omicron BA.2.11, BA.2.12.1 and BA.4/5 subvariants are becoming dominant in France, the USA and South Africa, respectively. In this study, we evaluated the sensitivity of these new Omicron subvariants (BA.2.11, BA.2.12.1 and BA.4/5) to eight therapeutic monoclonal antibodies (bamlanivimab, bebtelovimab, casirivimab, cilgavimab, etesevimab, imdevimab, sotrovimab and tixagevimab). Notably, we showed that although cilgavimab is antiviral against BA.2, BA.4/5 exhibits higher resistance to this antibody compared to BA.2. Since mutations are accumulated in the spike proteins of newly emerging SARS-CoV-2 variants, we suggest the importance of rapid evaluation of the efficiency of therapeutic monoclonal antibodies against novel SARS-CoV-2 variants.
Kosugi Yusuke、Kimura Izumi、Uriu Keiya、Sato Kei、The Genotype to Phenotype Japan (G2P-Japan) Consortium、Yamasoba Daichi、Ito Jumpei、Fujita Shigeru
The University of TokyoThe University of TokyoThe University of TokyoThe University of TokyoThe University of Tokyo||Kobe UniversityThe University of TokyoThe University of Tokyo
医药卫生理论医学研究方法药学
Kosugi Yusuke,Kimura Izumi,Uriu Keiya,Sato Kei,The Genotype to Phenotype Japan (G2P-Japan) Consortium,Yamasoba Daichi,Ito Jumpei,Fujita Shigeru.Sensitivity of novel SARS-CoV-2 Omicron subvariants, BA.2.11, BA.2.12.1, BA.4 and BA.5 to therapeutic monoclonal antibodies[EB/OL].(2025-03-28)[2025-08-02].https://www.biorxiv.org/content/10.1101/2022.05.03.490409.点此复制
评论